211796-64-4

Upstream product

• 955946-11-9 4-bromo-1-(dibromomethyl)-2-(trifluoromethyl)benzene 
• 959984-49-7 3-trifluoromethyl-4-[2-(dimethylamino)vinyl]benzonitrile 
• 211796-64-4 4-dibromo-2-(trifluoromethyl)benzaldehyde 
• 557-21-1 zinc(II) cyanide 
• 320-43-4 4-chloro-2-(trifluoromethyl)benzaldehyde 
• 2591-86-8 N-Formylpiperidine 
• 7657-09-2 1,4-dibromo-2-(trifluoromethyl)benzene 
• 707-72-2 o-trifluoromethyl-α,α-dichlorotoluene 
• 445-02-3 4-bromo-2-trifluoromethyl-aniline 
• 364-12-5 4-bromo-1-iodo-2-(trifluoromethyl)benzene 
• 68-12-2 N,N-dimethyl-formamide 
• 261952-06-1 4-methyl-3-(trifluoromethyl)benzonitrile 

Downstream Products

• 1378929-16-8 (E,E)-2,5-bis[2-(2-trifluoromethyl-4-cyanophenyl)ethenyl]-1,4-bis(diphenylamino)benzene 
• 1378929-17-9 (E,E)-2,5-bis[2-(2-trifluoromethyl-4-cyanophenyl)ethenyl]-1,4-bis[bis(4-tert-butylphenyl)amino]benzene 
• 1422127-41-0 C₂₁H₁₉F₃N₄OS 
• 104356-17-4 4-bromo-2-trifluoromethylbenzoyl chloride 

Relevant academic research and scientific papers

Discovery of potent colony-stimulating factor 1 receptor inhibitors by replacement of hinge-binder moieties

Tumor-associated macrophages (TAMs) are predominantly associated with tumor growth. Colony-stimulating factor 1 receptor (CSF1R) acts as a key regulator of TAM survival and differentiation and is a molecular target for cancer therapies. Herein, novel CSF1

2-benzoyl malonate compound as well as preparation method and application thereof

The invention discloses a 2-benzoyl malonate compound as well as a preparation method and application thereof. The invention provides a preparation method of an acetylbenzene compound shown as a formula III. The preparation method comprises the following step: in an organic solvent, in the presence of an acid and water, carrying out a deesterification reaction as shown in the specification on a 2-benzoyl malonate compound as shown in a formula I and/or a tautomer thereof to obtain the acetylbenzene compound as shown in a formula III, wherein X is F, Cl, Br or I; wherein R1 and R2 are each independently a C1-C4 alkyl group. By adopting the 2-benzoyl malonate compound disclosed by the invention, 4-halogenated-2-trifluoromethyl acetophenone can be prepared through one-step reaction, and the operation is simple and convenient.

Realizing n-Type Field-Effect Performance via Introducing Trifluoromethyl Groups into the Donor-Acceptor Copolymer Backbone

Developing a new strategy to obtain n-type organic semiconductors is crucial for the advance of organic electronics. We herein report the synthesis and investigation of a series of donor-acceptor-type diazaisoindigo-based copolymers, named PAIID-TFBVB-C1,

Highly chemoselective intermolecular cross-benzoin reactions using an: Ad hoc designed novel N-heterocyclic carbene catalyst

The design of a novel N-heterocyclic carbene catalyst incorporating a bulky yet highly electron-deficient N-aryl substituent has allowed the development of an efficient protocol for the first highly chemoselective intermolecular benzoin condensations between two non-identical aromatic aldehydes.

Preparation method of o-trifluoromethyl-4-halogenobenzaldehyde and intermediate of o-trifluoromethyl-4-halogenobenzaldehyde

The invention discloses a preparation method of o-trifluoromethyl-4-halogenobenzaldehyde and an intermediate of the o-trifluoromethyl-4-halogenobenzaldehyde. The preparation method comprises that under solvent-free conditions, in the presence of an acid a

Efficient three-component synthesis of diversely substituted tetrahydro-1H-cyclopenta[c]quinolines

The synthesis of highly functionalized substituted tetrahydro-1H-cyclopenta[c]quinoline (I) and its reduced derivatives hexahydro-1H-cyclopenta[c]quinolines (II) via Povarov reaction in high diastereoselectivity and high to moderate yields is described he

Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases

Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases. Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease

Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors

This work details the evaluation of a number of N-alkylated deoxynojirimycin derivatives on their merits as dual glucosylceramide synthase/neutral glucosylceramidase inhibitors. Building on our previous work, we synthesized a series of d-gluco and l-ido-configured iminosugars N-modified with a variety of hydrophobic functional groups. We found that iminosugars featuring N-pentyloxymethylaryl substituents are considerably more potent inhibitors of glucosylceramide synthase than their aliphatic counterparts. In a next optimization round, we explored a series of biphenyl-substituted iminosugars of both configurations (d-gluco and l-ido) with the aim to introduce structural features known to confer metabolic stability to drug-like molecules. From these series, two sets of molecules emerge as lead series for further profiling. Biphenyl-substituted l-ido-configured deoxynojirimycin derivatives are selective for glucosylceramidase and the nonlysosomal glucosylceramidase, and we consider these as leads for the treatment of neuropathological lysosomal storage disorders. Their d-gluco-counterparts are also potent inhibitors of intestinal glycosidases, and because of this characteristic, we regard these as the prime candidates for type 2 diabetes therapeutics.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

The present invention provides a novel compound having a superior activity as an ERR-alpha modulator and useful as an agent for the prophylaxis or treatment of ERR-alpha associated diseases. The present invention relates to a compound represented by the formula (1) wherein each symbol is as defined in the specification, or a salt thereof